Femasys updates corporate presentation on women’s health portfolio

Femasys ( (FEMY) ) just unveiled an announcement.

On May 13, 2026, Femasys Inc. posted an updated corporate slide presentation on its website, intended for use in ongoing meetings with investors, analysts and other stakeholders. The materials highlight the company’s diversified women’s health portfolio, including fertility and non-surgical permanent birth control products, its global regulatory approvals, scalable U.S. manufacturing and experienced leadership team, positioning Femasys to tap large, underserved markets amid favorable macro and policy trends.

The most recent analyst rating on (FEMY) stock is a Buy with a $1.50 price target. To see the full list of analyst forecasts on Femasys stock, see the FEMY Stock Forecast page.

Spark’s Take on FEMY Stock

According to Spark, TipRanks’ AI Analyst, FEMY is a Neutral.

The score is held back primarily by very large operating losses and sustained, sizable cash burn relative to revenue, indicating ongoing funding risk. Technicals are mixed with a longer-term downtrend despite near-term stabilization, while valuation offers limited support at a ~21x P/E and no dividend. The COO appointment is a modest positive catalyst for execution but secondary to the financial risk profile.

To see Spark’s full report on FEMY stock, click here.

More about Femasys

Femasys Inc. is a woman-founded, U.S.-based biomedical device company focused on women’s reproductive health. It develops and commercializes market-first, in-office solutions across fertility, permanent birth control and cervical cancer diagnosis, supported by in-house scalable manufacturing, extensive clinical validation and more than 200 issued patents.

Average Trading Volume: 505,883

Technical Sentiment Signal: Sell

Current Market Cap: $22.77M

See more data about FEMY stock on TipRanks’ Stock Analysis page.